Cipher Pharmaceuticals (CPH) Competitors

Cipher Pharmaceuticals logo
C$13.40 -0.77 (-5.43%)
As of 11/16/2026 04:00 PM Eastern

CPH vs. GUD, DHT.UN, THCX, CMED, and FRX

Should you buy Cipher Pharmaceuticals stock or one of its competitors? Cipher Pharmaceuticals's main competitors and comparable companies include Knight Therapeutics (GUD), DRI Healthcare Trust (DHT.UN), Hydropothecary (THCX), CanniMed Therapeutics (CMED), and Fennec Pharmaceuticals (FRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Cipher Pharmaceuticals (TSE:CPH) and Knight Therapeutics (TSE:GUD) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Cipher Pharmaceuticals currently has a consensus price target of C$17.00, suggesting a potential upside of 26.87%. Knight Therapeutics has a consensus price target of C$9.50, suggesting a potential downside of 20.30%. Given Cipher Pharmaceuticals' higher probable upside, equities analysts clearly believe Cipher Pharmaceuticals is more favorable than Knight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cipher Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cipher Pharmaceuticals has a beta of 1.292956, meaning that its share price is 29% more volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.507722, meaning that its share price is 151% less volatile than the broader market.

Cipher Pharmaceuticals has a net margin of 69.98% compared to Knight Therapeutics' net margin of 2.84%. Cipher Pharmaceuticals' return on equity of 25.48% beat Knight Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cipher Pharmaceuticals69.98% 25.48% 7.90%
Knight Therapeutics 2.84%2.03%0.51%

2.5% of Cipher Pharmaceuticals shares are held by institutional investors. Comparatively, 21.1% of Knight Therapeutics shares are held by institutional investors. 42.0% of Cipher Pharmaceuticals shares are held by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cipher Pharmaceuticals had 3 more articles in the media than Knight Therapeutics. MarketBeat recorded 4 mentions for Cipher Pharmaceuticals and 1 mentions for Knight Therapeutics. Knight Therapeutics' average media sentiment score of 0.72 beat Cipher Pharmaceuticals' score of 0.72 indicating that Knight Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cipher Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Knight Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cipher Pharmaceuticals has higher earnings, but lower revenue than Knight Therapeutics. Cipher Pharmaceuticals is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cipher PharmaceuticalsC$49.62M6.86C$11.41MC$1.1211.96
Knight TherapeuticsC$563.45M2.08-C$30.73MC$0.1674.50

Summary

Cipher Pharmaceuticals beats Knight Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

DRI Healthcare Trust (TSE:DHT.UN) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Cipher Pharmaceuticals has a net margin of 69.98% compared to DRI Healthcare Trust's net margin of 5.02%. Cipher Pharmaceuticals' return on equity of 25.48% beat DRI Healthcare Trust's return on equity.

Company Net Margins Return on Equity Return on Assets
DRI Healthcare Trust5.02% 2.06% 4.22%
Cipher Pharmaceuticals 69.98%25.48%7.90%

Cipher Pharmaceuticals has lower revenue, but higher earnings than DRI Healthcare Trust. Cipher Pharmaceuticals is trading at a lower price-to-earnings ratio than DRI Healthcare Trust, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DRI Healthcare TrustC$172.74M6.15C$9.73MC$1.0817.92
Cipher PharmaceuticalsC$49.62M6.86C$11.41MC$1.1211.96

DRI Healthcare Trust currently has a consensus price target of C$25.60, indicating a potential upside of 32.30%. Cipher Pharmaceuticals has a consensus price target of C$17.00, indicating a potential upside of 26.87%. Given DRI Healthcare Trust's stronger consensus rating and higher probable upside, equities research analysts clearly believe DRI Healthcare Trust is more favorable than Cipher Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DRI Healthcare Trust
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
Cipher Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Cipher Pharmaceuticals had 4 more articles in the media than DRI Healthcare Trust. MarketBeat recorded 4 mentions for Cipher Pharmaceuticals and 0 mentions for DRI Healthcare Trust. Cipher Pharmaceuticals' average media sentiment score of 0.72 beat DRI Healthcare Trust's score of 0.50 indicating that Cipher Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
DRI Healthcare Trust Positive
Cipher Pharmaceuticals Positive

DRI Healthcare Trust has a beta of 0.087008, meaning that its stock price is 91% less volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 1.292956, meaning that its stock price is 29% more volatile than the broader market.

0.3% of DRI Healthcare Trust shares are owned by institutional investors. Comparatively, 2.5% of Cipher Pharmaceuticals shares are owned by institutional investors. 0.1% of DRI Healthcare Trust shares are owned by company insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Cipher Pharmaceuticals beats DRI Healthcare Trust on 11 of the 17 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Hydropothecary?

Cipher Pharmaceuticals (TSE:CPH) and Hydropothecary (CVE:THCX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

2.5% of Cipher Pharmaceuticals shares are held by institutional investors. 42.0% of Cipher Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Cipher Pharmaceuticals had 4 more articles in the media than Hydropothecary. MarketBeat recorded 4 mentions for Cipher Pharmaceuticals and 0 mentions for Hydropothecary. Cipher Pharmaceuticals' average media sentiment score of 0.72 beat Hydropothecary's score of 0.00 indicating that Cipher Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Cipher Pharmaceuticals Positive
Hydropothecary Neutral

Cipher Pharmaceuticals has higher revenue and earnings than Hydropothecary.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cipher PharmaceuticalsC$49.62M6.86C$11.41MC$1.1211.96
HydropothecaryN/AN/AN/AN/AN/A

Cipher Pharmaceuticals presently has a consensus price target of C$17.00, indicating a potential upside of 26.87%. Given Cipher Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Cipher Pharmaceuticals is more favorable than Hydropothecary.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cipher Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Hydropothecary
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Cipher Pharmaceuticals has a net margin of 69.98% compared to Hydropothecary's net margin of 0.00%. Cipher Pharmaceuticals' return on equity of 25.48% beat Hydropothecary's return on equity.

Company Net Margins Return on Equity Return on Assets
Cipher Pharmaceuticals69.98% 25.48% 7.90%
Hydropothecary N/A N/A N/A

Summary

Cipher Pharmaceuticals beats Hydropothecary on 10 of the 10 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to CanniMed Therapeutics?

Cipher Pharmaceuticals (TSE:CPH) and CanniMed Therapeutics (TSE:CMED) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

2.5% of Cipher Pharmaceuticals shares are held by institutional investors. 42.0% of Cipher Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cipher Pharmaceuticals has higher revenue and earnings than CanniMed Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cipher PharmaceuticalsC$49.62M6.86C$11.41MC$1.1211.96
CanniMed TherapeuticsN/AN/AN/AN/AN/A

Cipher Pharmaceuticals has a net margin of 69.98% compared to CanniMed Therapeutics' net margin of 0.00%. Cipher Pharmaceuticals' return on equity of 25.48% beat CanniMed Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cipher Pharmaceuticals69.98% 25.48% 7.90%
CanniMed Therapeutics N/A N/A N/A

In the previous week, Cipher Pharmaceuticals had 4 more articles in the media than CanniMed Therapeutics. MarketBeat recorded 4 mentions for Cipher Pharmaceuticals and 0 mentions for CanniMed Therapeutics. Cipher Pharmaceuticals' average media sentiment score of 0.72 beat CanniMed Therapeutics' score of 0.00 indicating that Cipher Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Cipher Pharmaceuticals Positive
CanniMed Therapeutics Neutral

Cipher Pharmaceuticals currently has a consensus target price of C$17.00, indicating a potential upside of 26.87%. Given Cipher Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Cipher Pharmaceuticals is more favorable than CanniMed Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cipher Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
CanniMed Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Cipher Pharmaceuticals beats CanniMed Therapeutics on 10 of the 10 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Fennec Pharmaceuticals?

Cipher Pharmaceuticals (TSE:CPH) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Cipher Pharmaceuticals has higher earnings, but lower revenue than Fennec Pharmaceuticals. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cipher PharmaceuticalsC$49.62M6.86C$11.41MC$1.1211.96
Fennec PharmaceuticalsC$66.37M9.76-C$800.44K-C$0.12N/A

Cipher Pharmaceuticals has a beta of 1.292956, meaning that its share price is 29% more volatile than the broader market. Comparatively, Fennec Pharmaceuticals has a beta of 3.899825, meaning that its share price is 290% more volatile than the broader market.

Cipher Pharmaceuticals has a net margin of 69.98% compared to Fennec Pharmaceuticals' net margin of 2.55%. Cipher Pharmaceuticals' return on equity of 25.48% beat Fennec Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cipher Pharmaceuticals69.98% 25.48% 7.90%
Fennec Pharmaceuticals 2.55%4.17%8.88%

Cipher Pharmaceuticals currently has a consensus target price of C$17.00, suggesting a potential upside of 26.87%. Given Cipher Pharmaceuticals' higher possible upside, equities analysts plainly believe Cipher Pharmaceuticals is more favorable than Fennec Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cipher Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Fennec Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00

In the previous week, Cipher Pharmaceuticals had 3 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 4 mentions for Cipher Pharmaceuticals and 1 mentions for Fennec Pharmaceuticals. Fennec Pharmaceuticals' average media sentiment score of 0.88 beat Cipher Pharmaceuticals' score of 0.72 indicating that Fennec Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cipher Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Fennec Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

2.5% of Cipher Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.9% of Fennec Pharmaceuticals shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Cipher Pharmaceuticals and Fennec Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Cipher Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CPH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CPH vs. The Competition

MetricCipher PharmaceuticalsPharmaceuticals IndustryHealthcare SectorTSE Exchange
Market CapC$340.56MC$13.69BC$7.84BC$12.83B
Dividend YieldN/A2.58%2.46%4.65%
P/E Ratio11.9627.2534.0829.78
Price / Sales6.867.318.533.81
Price / Cash3.5315.7421.9334.92
Price / Book2.345.144.403.42
Net IncomeC$11.41MC$2.88BC$3.52BC$299.09M
7 Day Performance-1.69%-3.29%-4.42%-2.27%
1 Month Performance1.13%-3.77%-3.47%-3.40%
1 Year Performance0.07%-7.21%0.15%13.64%

Cipher Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CPH
Cipher Pharmaceuticals
3.1186 of 5 stars
C$13.40
-5.4%
C$17.00
+26.9%
+1.9%C$340.56MC$49.62M11.965
GUD
Knight Therapeutics
0.6557 of 5 stars
C$12.05
+0.2%
C$9.50
-21.2%
+94.1%C$1.18BC$563.45M75.31830
DHT.UN
DRI Healthcare Trust
2.8106 of 5 stars
C$19.47
-0.3%
C$25.60
+31.5%
+20.6%C$1.07BC$172.74M18.03N/A
THCX
Hydropothecary
N/AC$5.30
+6.6%
N/A+0.0%C$949.11MN/AN/AN/A
CMED
CanniMed Therapeutics
N/AN/AN/AN/AC$668.44MN/AN/A147,000

Related Companies and Tools


This page (TSE:CPH) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners